Gut Healing Peptide Stack: BPC-157, KPV, and Larazotide Protocol

Gut Healing Peptide Stack: BPC-157, KPV, and Larazotide Protocol

Key Takeaways:

• Gut health involves multiple distinct targets: intestinal lining integrity, intestinal permeability (tight junctions), and inflammation. Addressing only one rarely produces comprehensive improvement.
• This stack assigns three compounds to three distinct mechanisms: BPC-157 for lining repair and healing, KPV for intestinal anti-inflammatory signaling, and larazotide for tight junction regulation.
• For gut applications, oral administration of BPC-157 and KPV is often preferred over injection because both compounds survive partial digestion and work directly in the GI tract. Larazotide is oral only.
• The research for each individual compound is promising but primarily preclinical (BPC-157, KPV) or early-phase clinical (larazotide). No human trial has studied this combination.
• This protocol is most discussed in the context of IBD, leaky gut, and post-antibiotic gut disruption.

Important: This is not medical advice. The information below is for educational purposes only and summarizes published research on individual compounds. No gut healing peptide stacks have been studied in controlled clinical trials. These compounds are research peptides or investigational drugs not approved by the FDA for gut healing indications. Consult a gastroenterologist or qualified healthcare provider for any gut health condition. For a broader look at stacking principles and safety considerations, see our healing peptides guide. See our full medical disclaimer.

---

Why gut healing requires a multi-target approach

The gut is not one system. It is several overlapping systems that can fail in different ways simultaneously.

The intestinal epithelium (the lining that forms the barrier between your gut contents and your bloodstream) must constantly renew itself. Cells turn over every 3-5 days under normal conditions. In injured states, whether from IBD, NSAID use, infection, antibiotic disruption, or chronic stress, that renewal process is impaired. The lining becomes thinner, less structurally sound, and more permeable.

Tight junctions are the molecular seals between those epithelial cells. When tight junctions are compromised, gut contents can pass through the epithelial layer (intestinal permeability, colloquially "leaky gut"), triggering immune responses and systemic inflammation. Tight junction integrity and epithelial lining health are related but distinct problems.

Chronic gut inflammation, driven by cytokines like TNF-alpha, IL-6, and IL-1 beta, perpetuates both of these problems. Even if the structural damage begins to heal, ongoing inflammation continues to degrade the epithelium and tight junctions.

A single peptide addressing one of these three targets (lining repair, tight junction integrity, inflammation) leaves the other two partially unaddressed. This is the rationale for a multi-compound gut healing protocol.

BPC-157: The gut lining repair component

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found naturally in gastric juice. It was originally studied for its protective effects on the gastric mucosa and has since been investigated for a range of tissue healing applications.

For gut applications, BPC-157 is arguably the best-researched peptide in this class. Its documented mechanisms relevant to gut healing include:

• Mucosal healing: Multiple animal studies show BPC-157 accelerates healing of gastric ulcers, intestinal anastomoses, and colonic inflammation (PMID: 29898181)
• Angiogenesis at mucosal sites: Promotes new blood vessel formation in damaged gut tissue, improving oxygen and nutrient delivery to healing areas
• VEGF upregulation: Increases vascular endothelial growth factor, a key driver of mucosal healing
• Nitric oxide modulation: Regulates nitric oxide signaling, which plays a role in gut motility and mucosal protection
• Gut-brain axis effects: Modulates dopaminergic and serotonergic pathways via the enteric nervous system (PMID: 27142294), which may explain reported improvements in gut motility and visceral symptoms

For gut applications specifically, oral BPC-157 capsules are commonly used rather than subcutaneous injection. The rationale: BPC-157 was originally identified in gastric juice and appears to be partially stable in the GI tract. Taking it orally allows the compound to act directly on the intestinal mucosa throughout the gut, rather than entering the bloodstream first. Animal studies on intestinal healing use both routes with positive results.

Typical oral protocol for gut applications: 250-500 mcg orally, 1-2 times per day, taken on an empty stomach, for 8-12 weeks. Subcutaneous injection (same dose range) is used for systemic effects or by those who prefer injectable delivery. See our detailed resource on BPC-157 for the full mechanism breakdown, or our dedicated BPC-157 gut healing guide for the GI-specific research.

KPV: The anti-inflammatory component

KPV is a tripeptide (Lysine-Proline-Valine) that is a C-terminal fragment of alpha-MSH (alpha-melanocyte stimulating hormone). Alpha-MSH has well-documented anti-inflammatory properties in the gut, and KPV appears to retain these properties in a more stable, gut-stable form.

The research on KPV for gut inflammation is primarily preclinical but directly relevant:

• NF-kB inhibition: KPV reduces activation of NF-kB, the primary transcription factor driving inflammatory cytokine production in the intestinal mucosa. This is the mechanism behind its anti-inflammatory effects in IBD models.
• Cytokine reduction: Animal studies of colitis show KPV reduces TNF-alpha, IL-6, and IL-1 beta, the key pro-inflammatory cytokines involved in IBD pathology.
• Direct epithelial cell uptake: In vitro research shows KPV is actively transported into intestinal epithelial cells, where it works directly to reduce inflammatory signaling. This is significant because it suggests oral KPV acts locally in the gut rather than requiring systemic absorption.
• Colon-specific activity: Most published KPV research focuses on colonic inflammation, making it particularly relevant for people with colitis, Crohn's affecting the colon, or chronic colonic inflammation.

Because KPV appears to work directly on intestinal cells and can be taken orally, oral capsule administration is standard for gut applications. Typical protocol: 500 mcg to 1 mg orally, 1-2 times per day, 8-12 weeks.

KPV's mechanism is genuinely distinct from BPC-157's. BPC-157 drives structural repair; KPV dials down the inflammatory environment that makes structural repair difficult. Using both addresses the chicken-and-egg problem of gut healing: you cannot fully repair tissue while it is actively inflamed, and you cannot resolve inflammation while the structural integrity is compromised.

Larazotide: The tight junction component

Larazotide (AT-1001) is a synthetic octapeptide designed specifically to regulate tight junctions in the intestinal epithelium. It was developed by Alba Therapeutics and has been through multiple Phase 1 and Phase 2 clinical trials, making it the most clinically-tested compound in this stack.

The mechanism: larazotide is a zonulin antagonist. Zonulin is a protein that regulates tight junction permeability. Elevated zonulin opens tight junctions, increasing intestinal permeability. Larazotide blocks zonulin's receptor, helping to maintain tight junction integrity and reduce intestinal permeability.

Clinical research findings:

• Phase 2 trials in celiac disease patients showed larazotide reduced zonulin-mediated intestinal permeability and reduced inflammatory markers compared to placebo.
• Studies in celiac patients showed larazotide reduced symptom burden even in the context of accidental gluten exposure, suggesting it provides functional protection for the tight junction barrier.
• A Phase 2b trial showed reduced overall celiac disease symptoms, though subsequent Phase 3 results were mixed, which led to a pause in development. The mechanism is well-established even if the drug did not proceed to approval.

Larazotide is oral only. It is not available as an injection route. Typical research-use doses: 0.5-4 mg orally, 3 times per day, taken before meals.

Within this stack, larazotide addresses the specific problem that neither BPC-157 nor KPV targets directly: the regulatory control of tight junction opening and closing. BPC-157 repairs the structural tissue. KPV reduces inflammatory pressure on that tissue. Larazotide maintains the barrier function of the junctions between the cells.

Oral vs. injectable: why gut healing favors oral delivery

For most peptide applications, injection is considered the gold standard for bioavailability. Most peptides are degraded by digestive enzymes in the stomach and small intestine before they can be absorbed.

Gut healing is the major exception to this rule.

All three compounds in this stack work locally in the GI tract. The goal is not systemic circulation but direct contact with the gut mucosa, epithelial cells, and tight junctions. Oral administration achieves this more directly than injection.

BPC-157 has animal evidence supporting both oral and injectable efficacy for gut-specific outcomes, with some researchers arguing oral is superior for GI applications precisely because it ensures direct mucosal contact. KPV's epithelial cell uptake mechanism depends on oral delivery; an injectable KPV would bypass the intestinal mucosa entirely. Larazotide is oral only by design.

For systemic injuries (tendons, bones, organs outside the GI tract), subcutaneous BPC-157 is the standard. For gut-specific applications, the oral route is preferred for all three compounds.

Sample protocol

This is a commonly discussed framework in the peptide community. It is not a clinical protocol.

Weeks 1-12: Full Stack

• BPC-157: 250-500 mcg orally, twice daily, on an empty stomach (30 minutes before meals)
• KPV: 500 mcg to 1 mg orally, twice daily, with or without food
• Larazotide: 0.5-2 mg orally, 3 times per day, taken 15-30 minutes before meals

Weeks 12-16: Off Period

Stop all three compounds and assess symptoms. Some people cycle back in for a second 12-week course if gut symptoms return or persist.

Monitoring:

• Symptom diary tracking daily gut symptoms, stool consistency, bloating, and pain
• If available, biomarkers of intestinal permeability (lactulose/mannitol ratio, zonulin serum level)
• Inflammatory markers (CRP, fasting calprotectin if stool testing is accessible)

Who this stack is most relevant for

Conditions where this combination is most commonly discussed:

• Inflammatory bowel disease (IBD): Crohn's disease, ulcerative colitis. The anti-inflammatory (KPV) and lining-repair (BPC-157) mechanisms are directly relevant.
• Celiac disease: Larazotide was specifically developed and tested for this population.
• Post-antibiotic gut disruption: Antibiotics disrupt the microbiome and can compromise mucosal integrity. BPC-157 and KPV address the structural and inflammatory consequences.
• SIBO (small intestinal bacterial overgrowth): Often involves intestinal permeability and mucosal inflammation, though the primary SIBO treatment (eradication of bacterial overgrowth) must be addressed before or alongside any repair protocol.
• Non-specific leaky gut / intestinal permeability concerns: This is the broadest and most common use case, though "leaky gut" as a clinical diagnosis is debated.

Important caveat for IBD patients: BPC-157 has angiogenic properties. In the context of active, severe intestinal inflammation with potential ulceration or vascular fragility, discuss with your gastroenterologist before starting any angiogenic compound. This is a theoretical concern rather than a documented harm, but it warrants clinical supervision.

What this stack does not address

This protocol targets structural repair, tight junction integrity, and inflammatory signaling. It does not address:

• Microbiome restoration: Dysbiosis (microbiome imbalance) is a major driver of gut dysfunction. Probiotic and prebiotic strategies address this separately.
• Digestive enzyme insufficiency: If poor digestion is driving gut symptoms, enzyme supplementation is a more direct intervention.
• Motility disorders: IBS-predominant symptoms, constipation, or diarrhea-dominant patterns may not respond primarily to structural repair.
• Underlying triggers: If a dietary trigger (gluten, dairy, FODMAPs) is actively driving inflammation, removing the trigger is foundational. Peptides cannot outrun an ongoing inflammatory stimulus.

---

Frequently Asked Questions

Can this stack be used alongside prescription IBD medications? Potentially, but this requires gastroenterologist guidance. BPC-157's interactions with immunosuppressants commonly used in IBD (biologics, steroids) have not been studied. Do not add research peptides to an existing prescription IBD protocol without your prescribing physician's involvement.

How long before gut healing peptides show results? KPV's anti-inflammatory effects may be noticeable within 2-4 weeks for symptom relief. Structural repair with BPC-157 typically requires the full 8-12 week cycle for meaningful mucosal improvement. Larazotide's tight junction effects were measurable within the trial periods (generally 6-12 weeks).

Is BPC-157 safe for people with intestinal cancer history? This is a meaningful concern. BPC-157 promotes angiogenesis, and angiogenic compounds can theoretically support tumor vascularity. People with any cancer history should discuss with their oncologist before using angiogenic peptides. This applies to all angiogenic compounds, not just BPC-157 specifically.

Can this gut stack be combined with probiotics? Yes, and the combination is logical. Probiotics address microbiome composition. This stack addresses mucosal integrity, tight junctions, and inflammation. They target different systems and can work simultaneously. Take probiotics at a different time of day from the peptides for practical convenience.

What is the difference between taking BPC-157 orally versus as a capsule versus dissolving in water? The common approaches are: pre-made oral capsules from research vendors, or dissolving lyophilized BPC-157 powder in water for oral consumption. Both are forms of oral administration. Capsule form is more convenient and may protect some of the compound from early stomach acid exposure. Both are used in community protocols. For a primer on reconstituting peptide powder before oral or injectable use, see our how to reconstitute peptides guide.

---

Sources

1. Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." PMID: 29898181
2. Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157." PMID: 27142294
3. Dalmasso G, et al. "The peptide alpha-MSH inhibits TNF-alpha-induced NF-kB activation in intestinal epithelial cells." (KPV mechanism research on NF-kB inhibition and epithelial cell uptake.)
4. Fasano A, et al. "Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease." Lancet. 2000.
5. Paterson BM, et al. "The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study." Alimentary Pharmacology and Therapeutics. 2007.

---

The information in this article is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. See our full disclaimer.